4-Aminophenylacetic acidCAS# 1197-55-3 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1197-55-3 | SDF | Download SDF |
| PubChem ID | 14533 | Appearance | Powder |
| Formula | C8H9NO2 | M.Wt | 151 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 2-(4-aminophenyl)acetic acid | ||
| SMILES | C1=CC(=CC=C1CC(=O)O)N | ||
| Standard InChIKey | CSEWAUGPAQPMDC-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C8H9NO2/c9-7-3-1-6(2-4-7)5-8(10)11/h1-4H,5,9H2,(H,10,11) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
4-Aminophenylacetic acid Dilution Calculator
4-Aminophenylacetic acid Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 6.6225 mL | 33.1126 mL | 66.2252 mL | 132.4503 mL | 165.5629 mL |
| 5 mM | 1.3245 mL | 6.6225 mL | 13.245 mL | 26.4901 mL | 33.1126 mL |
| 10 mM | 0.6623 mL | 3.3113 mL | 6.6225 mL | 13.245 mL | 16.5563 mL |
| 50 mM | 0.1325 mL | 0.6623 mL | 1.3245 mL | 2.649 mL | 3.3113 mL |
| 100 mM | 0.0662 mL | 0.3311 mL | 0.6623 mL | 1.3245 mL | 1.6556 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Tranexamic acid
Catalog No.:BCN2710
CAS No.:1197-18-8
- 3',4'-Dihydroxyacetophenone
Catalog No.:BCN4775
CAS No.:1197-09-7
- Amadacycline methanesulfonate
Catalog No.:BCC1356
CAS No.:1196800-40-4
- Yucalexin P-17
Catalog No.:BCN6595
CAS No.:119642-82-9
- Moguisteine
Catalog No.:BCC4925
CAS No.:119637-67-1
- Naloxone benzoylhydrazone
Catalog No.:BCC5757
CAS No.:119630-94-3
- Arecaidine but-2-ynyl ester tosylate
Catalog No.:BCC6627
CAS No.:119630-77-2
- Sulfo-NHS-Biotin
Catalog No.:BCC3576
CAS No.:119616-38-5
- Olprinone Hydrochloride
Catalog No.:BCC1821
CAS No.:119615-63-3
- PF-3845
Catalog No.:BCC2326
CAS No.:1196109-52-0
- GSK2190915 sodium salt
Catalog No.:BCC5588
CAS No.:1196070-26-4
- 2-Hydroxyquinoxaline
Catalog No.:BCC8577
CAS No.:1196-57-2
- 5-Methylfurmethiodide
Catalog No.:BCC6707
CAS No.:1197-60-0
- PF-05212384 (PKI-587)
Catalog No.:BCC4987
CAS No.:1197160-78-3
- Sutchuenmedin A
Catalog No.:BCN6854
CAS No.:1197194-31-2
- UNC 0224
Catalog No.:BCC2430
CAS No.:1197196-48-7
- 2-Epitormentic acid
Catalog No.:BCN6084
CAS No.:119725-19-8
- Fupenzic acid
Catalog No.:BCN6085
CAS No.:119725-20-1
- Baohuoside VII
Catalog No.:BCN2889
CAS No.:119730-89-1
- TGR5 Receptor Agonist
Catalog No.:BCC4195
CAS No.:1197300-24-5
- Sazetidine A dihydrochloride
Catalog No.:BCC7468
CAS No.:1197329-42-2
- SDZ 205-557 hydrochloride
Catalog No.:BCC7246
CAS No.:1197334-02-3
- SB 206553 hydrochloride
Catalog No.:BCC7143
CAS No.:1197334-04-5
- Schizanthine G
Catalog No.:BCN1938
CAS No.:119736-74-2
Inhibition of Clostridium difficile toxin A-induced colitis in rats by APAZA.[Pubmed:15810644]
Dig Dis Sci. 2005 Mar;50(3):565-73.
A new compound, APAZA, consisting of a molecule of 5-aminosalicylic acid linked to one molecule of 4-Aminophenylacetic acid by an azo bond, was testedfor its ability to inhibit acute colitis in rats caused by Clostridium difficile toxin A. When administered chronically for 5 days in drinking water, APAZA significantly inhibited toxin A-induced myeloperoxidase activity, luminal fluid accumulation, and structural damage to the colon at doses of from 1 to 100 mg/kg x day. For comparison, sulfasalazine was administered in identical doses and was found to significantly inhibit toxin A-induced colitis only at the dose of 100 mg/kg x day. When 4-Aminophenylacetic acid alone was administered chronically in drinking water, it also inhibited toxin A-induced colonic inflammation at a dose of 100 mg/kg x day. In order to determine if 4-Aminophenylacetic acid has a direct anti-inflammatory effect on the colon rather than a systemic effect, 4-Aminophenylacetic acid was administered acutely to surgically prepared isolated colonic segments by intraluminal injection in anesthetized rats 30 min before toxin A was injected. 4-Aminophenylacetic acid strongly and significantly inhibited toxin A-induced colitis in this experiment at doses as low as 10 microg/segment. It is concluded that APAZA is a potent inhibitor of toxin A-induced colonic inflammation in rats and that its constituent, 4-Aminophenylacetic acid, is responsible for this increased protection against colitis compared to the 5-aminosalicylic acid component of sulfasalazine.
Peptide mimics as substrates for the intestinal peptide transporter.[Pubmed:9417040]
J Biol Chem. 1998 Jan 2;273(1):20-2.
4-Aminophenylacetic acid (4-APAA), a peptide mimic lacking a peptide bond, has been shown to interact with a proton-coupled oligopeptide transporter using a number of different experimental approaches. In addition to inhibiting transport of labeled peptides, these studies show that 4-APAA is itself translocated. 4-APAA transport across the rat intact intestine was stimulated 18-fold by luminal acidification (to pH 6.8) as determined by high performance liquid chromatography (HPLC); in enterocytes isolated from mouse small intestine the intracellular pH was reduced on application of 4-APAA, as shown fluorimetrically with the pH indicator carboxy-SNARF; 4-APAA trans-stimulated radiolabeled peptide transport in brush-border membrane vesicles isolated from rat renal cortex; and in Xenopus oocytes expressing PepT1, 4-APAA produced trans-stimulation of radiolabeled peptide efflux, and as determined by HPLC, was a substrate for translocation by this transporter. These results with 4-APAA show for the first time that the presence of a peptide bond is not a requirement for rapid translocation through the proton-linked oligopeptide transporter (PepT1). Further investigation will be needed to determine the minimal structural requirements for a molecule to be a substrate for this transporter.
